Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

NCT00020475 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

NIH

Sponsor class

Conditions

Extraocular Extension Melanoma
Recurrent Intraocular Melanoma

Interventions

DRUG: gp100 antigen
DRUG: interleukin-2
DRUG: MART-1 antigen
DRUG: Montanide ISA-51

Sponsor

National Cancer Institute (NCI)